Neuroplast holds European Orphan Designations with a fast-track development path to market authorization, with ten-year market exclusivity, for traumatic spinal cord injury and frontotemporal dementia. Safety and significant benefits are proven for traumatic spinal cord injury in a completed Phase II placebo-controlled trial. 
 

Neuroplast is offering a unique investment opportunity to bring the Neuro-Cells platform to the market in Europe, US, and the Middle East for the primary indication subacute spinal cord injury and to enable the development of a multidose low-invasive administration form of Neuro-Cells to treat Alzheimer’s Disease.
 

We value our stakeholders and invite you to become part of our mission to give back perspective.
 

Please contact us via Hans de Munter (h.demunter@neuroplast.com)